Replies to post #150832 on Biotech Values

[dav1234]

Some cheapies on deck..only question is how cheap

[Praveen]

Upfront and milestone payments are 1.2B$. Abt also paid for the 2nd gen and it looks like the whole platform will be in question. Actually Huff the CEO wanted to go to the FDA with p2b results but Abbott convinced him otherwise.

[DewDiligence]

Reata’s Bardoxolone is alive and kicking (although no longer licensed to ABBV):

http://finance.yahoo.com/news/reata-present-initial-phase-2-120000755.html